Fig. 2: Univariable comparisons of progression-free survival for selected risk factors were done by log-rank tests. | Bone Marrow Transplantation

Fig. 2: Univariable comparisons of progression-free survival for selected risk factors were done by log-rank tests.

From: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

Fig. 2

a Shows progression-free survival by sensitivity to chemoimmunotherapy (CIT). Patients who were not exposed to CIT are shown in green, patients with CIT-sensitive CLL in brown and patients with poorly responsive/refractory CLL in violet. b Shows PFS by pathway-inhibitor failure. Patients who had only been exposed to idelalisib and responsive disease are displayed in green, all remaining patients are displayed in violet. c Shows PFS of patients by pathway-inhibitor (PI)- or CIT failure. Patients who had failed neither PI nor CIT are shown in green. Patients who had failed either PI or CIT are shown in brown color. The remaining patients (violet curve), who have failed both, CIT and PI, have the worst outcome.

Back to article page